Cytokines as Biomarkers in Systemic Lupus Erythematosus: Value for Diagnosis and Drug Therapy

Abstract

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease. The disease is characterized by activation and dysregulation of both the innate and the adaptive immune systems. The autoimmune response targets self-molecules including cell nuclei, double stranded DNA and other intra and extracellular structures. Multiple susceptibility genes within the immune system have been identified, as well as disturbances in different immune pathways. SLE may affect different organs and organ systems, and organ involvement is diverse among individuals. A universal understanding of pathophysiological mechanism of the disease, as well as directed therapies, are still missing. Cytokines are immunomodulating molecules produced by cells of the immune system. Interferons (IFNs) are a broad group of cytokines, primarily produced by the innate immune system. The IFN system has been observed to be dysregulated in SLE, and therefore IFNs have been extensively studied with a hope to understand the disease mechanisms and identify novel targeted therapies. In several autoimmune diseases identification and subsequent blockade of specific cytokines has led to successful therapies, for example tumor necrosis factor-alpha (TNF-α) inhibition in rheumatoid arthritis. Authors of this review have sought corresponding developments in SLE. In the current review, we cover the actual knowledge on IFNs and other studied cytokines as biomarkers and treatment targets in SLE.

Placental damage in pregnancies with systemic lupus erythematosus: A narrative review

“…Interferon- α has been a critical and the most studied cytokine in the pathogenesis of SLE ( 85 ). As is known about half of lupus patients have a predominant expression of interferon-induced genes in their peripheral blood mononuclear cells, which is an enhanced type I interferon gene signature ( 86 ). A cohort conducted at Karolinska observed that high IFN-α activity correlates positively with disease activity scores (SLEDAI and SLAM) and with the active involvement of specific organs: e.g., nephritis, arthritis, lymphadenopathy, fatigue, and weight loss.…”

Healthy Immunity on Preventive Medicine for Combating COVID-19

“…This immune response provides the initial defense against invading pathogens [ 26 ]. The innate system involves skin, epithelial tissue linings, respiratory tract, and genitourinary tract, as well as the mucus layers that coat these tissues, and includes neutrophils, monocytes, macrophages, cytokines, and specific proteins [ 27 , 28 ]. Importantly, skin provides a solid and sturdy barrier for the internal milieu against environmental toxins, ultraviolet radiation, bacteria, and germs.…”

Systemic lupus erythematosus: history and modernity

“…Прогресс фундаментальных исследований, способствующих лучшему пониманию механизмов иммунопатологии СКВ, послужил теоретическим обоснованием для разработки новых подходов к фармакотерапии СКВ, в первую очередь генно-инженерных биологических препаратов (ГИБП) [44,[67][68][69][70][71][72][73], направленных на блокирование широкого спектра молекулярных и клеточных биологических «мишеней», участвующих в развитии воспаления и аутоиммунитета: цитокины и ИФН типа I, компоненты комплемента, внутриклеточные сигнальные пути и факторы транскрипции, модулирующие активность цитокинов и иммунометаболических процессов в клетках иммунной системы, патологическую активацию В-клеток и плазматических клеток (табл. 1).…”